- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05823896
imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)
An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering From Post-COVID
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At present there is no curative treatment for post-acute COVID-19 syndrome (PACS). Treatment is focused on symptom management and individualized rehabilitation. There is data indicating SARS-CoV-2 viral persistence and chronic immune system activation in PACS. We are proposing an interventional, randomized and placebo-controlled clinical intervention trial of nirmatrelvir/ritonavir (300/100 mg) or placebo/ritonavir (100mg), twice daily for 15 days, in patients suffering from severe PACS. Patients meeting the WHO definition of severe PACS will be identified from a database of 988 patients cared for by the Karolinska University Hospital Post-COVID clinics since May 2020, and in whom extensive clinical and laboratory examinations have been performed. A total of 400 patients will be enrolled in this study and these will be randomized in a 2:1 ratio to receive either nirmatrelvir/ritonavir or placebo/ritonavir. The study will include deep exploratory systems-level analyses of the immune system in PACS patients, including changes induced by nirmatrelvir/ritonavir (Paxlovid®) treatment. The purpose of this study is to evaluate the efficacy of nirmatrelvir/ritonavir for its potential ability to provide sustained improvement in quality of life, in non-hospitalized patients with post-COVID, a patient group with high unmet medical needs.
Hypothesis: Nirmatrelvir/ritonavir (Paxlovid®) improves health-related quality of life measured using the EQ-5D-5L VAS scale, as compared to placebo/ritonavir, in objective and pre-defined clinical phenotypes: postural orthostatic tachycardia syndrome (POTS), microvascular dysfunction, inappropriate sinus tachycardia, persistent fever, post exertional malaise (PEM), fatigue, brain fog, dyspnea, dysfunctional breathing patterns or inflammatory phenotypes (increased plasma D-dimer, CRP, ESR and ferritin).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Petter Brodin, MD, PhD
- Phone Number: +46 8 52481396
- Email: petter.brodin@ki.se
Study Contact Backup
- Name: Judith Bruchfeld, MD, PhD
- Email: judith.bruchfeld@ki.se
Study Locations
-
-
-
Stockholm, Sweden, SE171 77
- Recruiting
- Karolinska Institutet
-
Contact:
- Petter Brodin, MD PhD
- Phone Number: +46 8 52481396
- Email: petter.brodin@ki.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The subject has given written consent to participate in the study.
- ≥18 years of age at the time of the Screening Visit.
- Post-acute COVID-19 syndrome (PACS) according to the WHO definition.
- EQ-5D-5L VAS< 50
- All fertile participants must agree to use a highly effective method of contraception for the duration of the study and 28 days after last intake of the IMP.
Exclusion Criteria:
General exclusion criteria
- Other non-related conditions with PACS like symptoms.
- Renal function eGFR eGFRCysC < 60 mL/min/1.73 m2.
- Not able to comply with the study protocol.
- Previous Paxlovid treatment.
- Pregnancy or breastfeeding.
- Drug-drug interaction with ongoing treatment, including concomitant use of any medications or substances that are strong inducers of CYP3A4 within 28 days prior to first dose of nirmatrelvir/ritonavir and during study treatment.
- Participants who are planning or considering vaccination (including boosters) through Study Day 45.
- Active COVID-19 infection as verified by SARS CoV-2 positive antigen test.
Self-reported medical conditions, including:
- Type 1 or Type 2 diabetes mellitus.
- Chronic kidney disease.
- Neurodevelopmental disorders (e.g., cerebral palsy, Down's syndrome) or other conditions that confer medical complexity (e.g., genetic or metabolic syndromes and severe congenital anomalies).
- Active cancer other than localized skin cancer, including those requiring treatment including palliative treatment), as long as the treatment is not among the prohibited medications that must be administered/continued during the trial period.
- Immunosuppressive disease (e.g., bone marrow or organ transplantation or primary immune deficiencies) OR prolonged use of immune-weakening medications:
i. Has received corticosteroids equivalent to prednisone ≥20 mg daily for at least 14 consecutive days within 30 days prior to study entry.
ii. Has received treatment with biologics (e.g., infliximab, ustekinumab, etc.), immunomodulators (e.g., methotrexate, 6MP, azathioprine, etc.), or cancer chemotherapy within 90 days prior to study entry.
iii. HIV infection with CD4+ cell count <200/mm3.
- History of hospitalization for the medical treatment of acute COVID-19
- Current need for hospitalization or anticipated need for hospitalization within 48 hours after randomization in the clinical opinion of the site investigator.
Prior/Concomitant Therapy:
- Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance, and for which elevated plasma concentrations may be associated with serious and/or life-threatening events during treatment and for 4 days after the last dose of nirmatrelvir/ritonavir. List of potential interactions provided by Pfizer provided in Appendix A.
- Has received or is expected to receive monoclonal antibody treatment, antiviral treatment (e.g., molnupiravir), or convalescent COVID-19 plasma.
Prior/Concurrent Clinical Study Experience:
- Is unwilling to abstain from participating in another interventional clinical study with an investigational compound or device, including those for post-COVID-19 therapeutics, through the long-term follow-up visit.
- Previous administration with any investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
Known prior participation in this trial or other trial involving nirmatrelvir.
Diagnostic Assessments:
Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit):
- AST or ALT level ≥2.5 X ULN
- Total bilirubin ≥2 X ULN (≥3 X ULN for Gilbert's syndrome)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nirmatrelvir/ritonavir
Oral nirmatrelvir/ritonavir (Paxlovid) 300/100 mg twice daily for 15 days
|
300/100 mg tablet twice daily (q12h) administered orally for 15 days
Other Names:
|
Placebo Comparator: Placebo/ritonavir
Oral placebo/ritonavir 100 mg twice daily for 15 days
|
100mg tablet twice daily (q12h) administered orally for 15 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in quality of life at day 16
Time Frame: Baseline and day 16
|
The effect of oral administration of nirmatrelvir/ritonavir on quality of life measured as change from baseline using the EQ-5D-5L VAS scale.
|
Baseline and day 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in quality of life at days 45 and 90
Time Frame: Baseline and days 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on quality of life measured as change from baseline using the EQ-5D-5L VAS scale.
|
Baseline and days 45 and 90
|
Change from baseline in hemodynamic response at days 45 and 90
Time Frame: Baseline and days 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on hemodynamic response (only patients diagnosed with postural orthostatic tachycardia syndrome, POTS).
Change from baseline in delta maximum heart rate during active standing test.
|
Baseline and days 45 and 90
|
Change from baseline in fever in patients with POTS at days 45 and 90
Time Frame: Baseline and days 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on fever (only patients diagnosed with POTS).
Change from baseline in POTS-specific symptoms as measured by using the Malmo POTS score, MAPS.
|
Baseline and days 45 and 90
|
Change from baseline in endothelial function at day 45
Time Frame: Baseline and day 45
|
The effect of oral administration of nirmatrelvir/ritonavir on reactive hyperemia index.
Change from baseline in endothelial function measured using the EndoPat® device.
|
Baseline and day 45
|
Change from baseline in heart rate at days 45 and 90
Time Frame: Baseline and days 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on 24-h average heart rate.
Change from baseline in heart rate using ECG monitoring device.
|
Baseline and days 45 and 90
|
Change from baseline in fever at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on fever.
Change from baseline in body temperature.
|
Baseline and days 16, 45 and 90
|
Change from baseline in physical capacity at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on physical capacity.
Change from baseline as measured by 6-minute walk test.
|
Baseline and days 16, 45 and 90
|
Change from baseline in handgrip strength at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on handgrip strength.
Change from baseline as measured by JAMAR hand dynamometer.
|
Baseline and days 16, 45 and 90
|
Change from baseline in physical activity at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on physical activity.
Change from baseline as measured by accelerometer.
|
Baseline and days 16, 45 and 90
|
Change from baseline in post-exertional malaise at day 90
Time Frame: Baseline and day 90
|
The effect of oral administration of nirmatrelvir/ritonavir on post-exertional malaise.
Change from baseline in total score as measured by the Post-Exertional Malaise (PEM) short form.
|
Baseline and day 90
|
Change from baseline in fatigue at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on fatigue.
Change from baseline as measured by the fatigue severity scale (FSS) and mental fatigue scale (MFS).
|
Baseline and days 16, 45 and 90
|
Change from baseline in cognitive dysfunction at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on cognitive dysfunction.
Change from baseline over time as measured by the Montreal Cognitive Assessment (MoCA) test.
|
Baseline and days 16, 45 and 90
|
Change from baseline in dyspnea at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on dyspnea measured as change from baseline in respiratory symptoms using the Chronic obstructive disease assessment (CAT) and Modified Medical Research Council (mMRC) tests.
|
Baseline and days 16, 45 and 90
|
Change from baseline in dysfunctional breathing patterns, maximum inspiratory pressure and lung function at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on dysfunctional breathing patterns, maximum inspiratory pressure, and lung function.
Change from baseline in Njimegen questionnaire, maximal inspiratory pressure (MIP), forced vital capacity (FVC) and forced expiratory volume in one second (FEV1).
|
Baseline and days 16, 45 and 90
|
Change from baseline in plasma biomarkers at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on plasma biomarkers.
Change from baseline in the following plasma biomarkers: D-dimer, CRP, ESR, ferritin, NTproBNP and LD.
|
Baseline and days 16, 45 and 90
|
Change from baseline in dysautonomia at days 45 and 90
Time Frame: Baseline and days 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on dysautonomia symptoms.
Change from baseline as measured using the Composite Autonomic Symptom Score (Compass31) questionnaire.
|
Baseline and days 45 and 90
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in breathing patterns at days 16, 45 and 90
Time Frame: Baseline and days 16, 45 and 90
|
The effect of oral administration of nirmatrelvir/ritonavir on breathing pattern.
Change from baseline in dynamic spirometry measurements.
|
Baseline and days 16, 45 and 90
|
Change from baseline in persistence of SARS-CoV-2 virus at day 16
Time Frame: At baseline and day 16
|
The effect of oral administration of nirmatrelvir/ritonavir on persistence of SARS-CoV-2 virus as measured by: Protein profiling using Olink Explore Inflammation panel. Nucleosome-profiling (using Volition) and circulating spike (using SIMOA™, Quanterix). PBMC profiling for scTCR-sequencing (using BD Rhapsody) with assessment of Super-Ag-mediated T-cell activation. Immune system signatures associated with disease states using RNA-sequencing of stabilized whole blood (PaxGene). |
At baseline and day 16
|
Change from baseline in immune cell function at day 16
Time Frame: At baseline and day 16
|
The effect of oral administration of nirmatrelvir/ritonavir on changes in immune cell function as assessed by high-dimensional cytometry.
|
At baseline and day 16
|
Change from baseline in relationships between genotypes and immune function at day 16
Time Frame: At baseline and day 16
|
The effect of oral administration of nirmatrelvir/ritonavir on the relationship between genotypes and immune function at the molecular level.
Circulating protein levels adjusted for DNA-variants.
|
At baseline and day 16
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Runold, MD, PhD, Karolinska University Hospital
Publications and helpful links
General Publications
- Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, Rodrigues NB, Subramaniapillai M, Di Vincenzo JD, Cao B, Lin K, Mansur RB, Ho RC, Rosenblat JD, Miskowiak KW, Vinberg M, Maletic V, McIntyre RS. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022 Mar;101:93-135. doi: 10.1016/j.bbi.2021.12.020. Epub 2021 Dec 29.
- Sundaram A, Vaughan B, Kost K, Bankole A, Finer L, Singh S, Trussell J. Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth. Perspect Sex Reprod Health. 2017 Mar;49(1):7-16. doi: 10.1363/psrh.12017. Epub 2017 Feb 28.
- Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, Polici M, Rucci C, Bracci B, Nicolai M, Cremona A, De Dominicis C, Laghi A. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. Radiology. 2021 Nov;301(2):E396-E405. doi: 10.1148/radiol.2021210834. Epub 2021 Jul 27.
- Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, Li Y, Cao Y, Gu J, Wu H, Shi H. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021 Apr;299(1):E177-E186. doi: 10.1148/radiol.2021203153. Epub 2021 Jan 26.
- Goh D, Lim JCT, Fernaindez SB, Joseph CR, Edwards SG, Neo ZW, Lee JN, Caballero SG, Lau MC, Yeong JPS. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. 2022 Sep 5;13:939989. doi: 10.3389/fimmu.2022.939989. eCollection 2022. Erratum In: Front Immunol. 2022 Oct 06;13:1036894.
- Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med (Lausanne). 2022 Sep 23;9:1003103. doi: 10.3389/fmed.2022.1003103. eCollection 2022.
- Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simon-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
- Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M, Chan PLS, Demers N, Corrigan B, Damle B. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment. Clin Pharmacol Ther. 2022 Oct;112(4):892-900. doi: 10.1002/cpt.2688. Epub 2022 Jul 5.
- Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis. 2023 Feb 8;76(3):e487-e490. doi: 10.1093/cid/ciac722.
Helpful Links
- Recommendations related to contraception and pregnancy testing in clinical trials
- European Medicines Agency Assessment Report for Paxlovid
- Information related to Paxlovid
- Late breaking abstract 2021 ERS International Congress - Early follow-up of hospitalised and non-hospitalised patients with Covid-19 in a Swedish setting
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Orthostatic Intolerance
- Chronic Disease
- COVID-19
- Syndrome
- Disease
- Inflammation
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Post-Acute COVID-19 Syndrome
- Post-Infectious Disorders
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Nirmatrelvir
- Nirmatrelvir and ritonavir drug combination
Other Study ID Numbers
- KI-PROLIFIC-2023
- 2022-003855-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Nirmatrelvir/ritonavir
-
PfizerWithdrawnCOVID-19 Drug Treatment
-
Chinese University of Hong KongCompletedCOVID-19 | Chronic Kidney Disease stage4 | Chronc Kidney Disease Stage 5Hong Kong
-
Chinese PLA General HospitalRecruitingCOVID-19 | Renal Insufficiency, ChronicChina
-
PfizerCompletedSARS-CoV-2 InfectionJapan
-
PfizerActive, not recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityLuoyang Central Hospital; Nanyang Central Hospital; The Fifth People's Hospital... and other collaboratorsCompletedCOVID-19 | AzvudineChina
-
Universidade do PortoCentro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS); Rede... and other collaboratorsActive, not recruiting
-
PfizerRecruiting
-
Azienda Ospedaliera Universitaria Integrata VeronaAgenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di...Completed